Prostamax vs Tadalafil Peptide
A side-by-side research comparison of Prostamax and Tadalafil Peptide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Prostamax | Tadalafil Peptide |
|---|---|---|
| Full name | Prostamax (Prostate Peptide Bioregulator) | Tadalafil-Peptide Conjugate (Experimental) |
| Category | Sexual Health | Sexual Health |
| Status | Research compound (peptide bioregulator) | Research compound |
| Mechanism | As a signal peptide, it is proposed to regulate gene expression in prostate tissue, supporting normal prostatic function, reducing inflammation-related dysfunction, and maintaining healthy urogenital tissue. | CPP moiety facilitates targeted PDE5 inhibitor delivery to penile smooth muscle. Local PDE5 inhibition increases cGMP for NO-mediated vasodilation with reduced systemic exposure. |
| Molecular weight | ~ (short peptide) | ~2,500 Da (conjugate) |
| Half-life | Short (peptide) | 8-12 hours |
| Bioavailability | Oral (encapsulated) or subcutaneous | Targeted (topical/local) |
| Typical dose | ~1-2 capsules/day or short injectable courses | 1-5 mg equivalent |
| Frequency | Once daily | As needed |
| Route | Oral capsule or subcutaneous | Topical or local injection |
Prostamax reported benefits
- Prostate tissue support (proposed)
- Male urogenital health
- Anti-inflammatory tissue signaling (proposed)
- Short course-based protocol
Tadalafil Peptide reported benefits
- Targeted PDE5 inhibition
- Reduced systemic side effects
- Potentially faster onset
- Lower dose requirement
Related comparisons
Research and educational reference only. Not medical advice.